2006 JASN IMPACT FACTOR 7.371	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) All Versions of this Article: ASN.2007111204v1 19/4/656    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Textor, S. C. PubMed PubMed Citation Articles by Textor, S. C.

Atherosclerotic Renal Artery Stenosis: Overtreated but Underrated?

Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota

Correspondence: Dr. Stephen C. Textor, Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN 55905. Phone: 507-284-4083; Fax: 507-284-1161; E-mail: textor.stephen{at}mayo.edu

Despite evidence of only moderate clinical benefit, application of renal endovascular stent procedures has increased at least four-fold in the past decade. Medicare is reviewing national coverage regarding reimbursement, questioning whether outcome data warrant many of these procedures. Several prospective, randomized trials are now in progress to compare outcomes with optimized medical therapy with and without stenting. Current imaging methods establish primarily the presence and severity of vascular occlusive disease. Optimal treatment for individual patients remains in flux and is reviewed here. Most important, nephrologists await development of tools to predict reliably when renal parenchymal injury is beyond recovery and/or when revascularization can produce meaningful salvage of kidney function.

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673